Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland-a consensus report

Lupus

Volumn 21, Issue 4, 2012, Pages 386-401

  Aringer, M ^a   Burkhardt, H ^b   Burmester, G R ^c   Fischer Betz, R ^d   Fleck, M ^e   Graninger, W ^f   Hiepe, F ^c   Jacobi, A M ^g   Kotter I ^h   Lakomek, H J ⁱ   Lorenz, H M ^j   Manger, B ^k   Schett, G ^k   Schmidt, R E ^l   Schneider, M ^d   Schulze Koops, H ^m   Smolen, J S ⁿ   Specker, C ^o   Stoll, T ^p   Strangfeld, A ^q   Tony, H P ^r   Villiger, P M ^s   Voll, R ^t   Witte, T ^l   Dorner T ^c   more..

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY OF GRAZ   (Austria)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ KLINIKUM MINDEN   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m UNIVERSITY OF MUNICH   (Germany)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o UNIVERSITY HOSPITAL ESSEN   (Germany)

^p Kantonsspital Schaffhausen   (Switzerland)

^q Deutsches Rheumaforschungsinstitut   (Germany)

^r UNIVERSITY OF WÜRZBURG   (Germany)

^s UNIVERSITY OF BERN   (Switzerland)

^t UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

adverse events; biological response modifiers; consensus; evidence; off label treatment; systemic lupus erythematosus

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; ETANERCEPT; GOLIMUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; TOCILIZUMAB;

ANTIPHOSPHOLIPID SYNDROME; ARTHRITIS; ARTICLE; AUSTRIA; CONSENSUS; GERMANY; HEMATOLOGIC DISEASE; HUMAN; INFLAMMATION; LUNG DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; MENTAL DISEASE; NEUROLOGIC DISEASE; OFF LABEL DRUG USE; PRIORITY JOURNAL; SWITZERLAND; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 84858643051     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203311426569     Document Type: Article

References (155)

1. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 ; 82: 299-308 (Pubitemid 37229465)
2. Bertsias G, Ioannidis JP, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008 ; 67: 195-205 (Pubitemid 351183308)
3. Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis. 2010 ; 69: 1603-1611
4. Ronnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010 ; 6: 339-347
5. Dorner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009 ; 5: 433-441
6. Aringer M, Crow MK. A bridge between interferon-alpha and tumor necrosis factor in lupus. J Rheumatol. 2008 ; 35: 1473-1476
7. Lipsky PE, Dorner T. The red wolf remains a wily foe. Nat Rev Rheumatol. 2010 ; 6: 307-308
8. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
9. Furie R, Looney RJ, Rovin B, et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR trial. Arthritis Rheum. 2009 ; 60 (Suppl 10). S429 - S429
10. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 ; 62: 3077-3087
11. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum. 2009 ; 61: 482-487
12. Jonsdottir T, Gunnarsson I, Risselada A, Henriksson EW, Klareskog L, van Vollenhoven RF. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis. 2008 ; 67: 330-334 (Pubitemid 351281266)
13. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther. 2011 ; 13: R75 - R75
14. Ramos-Casals M, Garcia-Hernandez FJ, De Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010 ; 28: 468-476
15. Jonsdottir T, Gunnarsson I, Mourao AF, Lu TY, van Vollenhoven RF, Isenberg D. Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. Rheumatology (Oxford). 2010 ; 49: 1502-1504
16. Marenco J, Fernandez-Nebro A, Lopez-Longo FJ, et al. and LESIMAB. Effectiveness and safety of rituximab in patients with systemic lupus erythematosus refractory to standard therapy. Ann Rheum Dis. 2010 ; 69 (Suppl 3). 554-554
17. van Vollenhoven RF, Jacobsen S, Petri M, et al. and SLICC Group. Biologics use in SLE in 5 centers - data from the international registry for biologics in SLE (IRBIS). Ann Rheum Dis. 2010 ; 69 (Suppl 3). 558-558
18. Vital EM, Dass S, Buch MH, et al. Treatment of SLE with B cell depletion: predicting response and managing loss of response. Ann Rheum Dis. 2010 ; 69 (Suppl 3). 558-558
19. Bertsias GK, Ioannidis JP, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010 ; 69: 2074-2082
20. Matsumura R, Umemiya K, Sugiyama T, et al. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol. 2009 ; 27: 416-421
21. Aringer M, Houssiau F, Gordon C, et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford). 2009 ; 48: 1451-1454
22. Moosig F, Zeuner R, Renk C, Schroder JO. IL-1RA in refractory systemic lupus erythematosus. Lupus. 2004 ; 13: 605-606 (Pubitemid 39145491)
23. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005 ; 64: 630-633 (Pubitemid 40469097)
24. Griffiths B, Emery P, Ryan V, et al. The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. Rheumatology (Oxford). 2010 ; 49: 723-732
25. Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol. 2009 ; 20: 901-911
26. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 2006 ; 1: 925-932
27. Zavada J, Pesickova S, Rysava R, et al. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus. 2010 ; 19: 1281-1289
28. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228 (Pubitemid 41697285)
29. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. 2010 ; 62: 211-221
30. Ginzler EM, Appel GB, Dooley MA, et al. Aspreva lupus management study (ALMS): maintenance results. Arthritis Rheum. 2010 ; 62 (Suppl 10). S871 - S872
31. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010 ; 69: 2083-2089
32. Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford). 2005 ; 44: 1317-1321 (Pubitemid 41487969)
33. Radhakrishnan J, Moutzouris DA, Ginzler EM, Solomons N, Siempos II, Appel GB. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010 ; 77: 152-160
34. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005 ; 16: 1076-1084 (Pubitemid 41710318)
35. Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford). 2002 ; 41: 876-882
36. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004 ; 50: 2580-2589 (Pubitemid 39062719)
37. Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, et al. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients. Lupus. 2010 ; 19: 213-219
38. Gunnarsson I, Sundelin B, Jonsdottir T, Jacobson SH, Henriksson EW, van Vollenhoven RF. Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 2007 ; 56: 1263-1272 (Pubitemid 46608651)
39. Tokunaga M, Saito K, Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007 ; 66: 470-475 (Pubitemid 46580466)
40. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 ; 62: 222-233
41. Lee T, Oh KH, Joo KW, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus. 2010 ; 19: 974-980
42. Cortes-Hernandez J, Torres-Salido MT, Medrano AS, Tarres MV, Ordi-Ros J. Long-term outcomes-mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant. 2010 ; 25: 3939-3948
43. Szeto CC, Kwan BC, Lai FM, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008 ; 47: 1678-1681
44. Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum. 2010 ; 62: 542-552
45. Kuhn A, Ochsendorf F, Bonsmann G. Treatment of cutaneous lupus erythematosus. Lupus. 2010 ; 19: 1125-1136
46. Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 ; 47: 920-923 (Pubitemid 351796385)
47. Bauernfeind B, Aringer M, Prodinger B, et al. Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise. Arthritis Rheum. 2009 ; 61: 21-28
48. Furie R, Zamani O, Wallace D, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity and severe flares in seropositive SLE patients: BLISS-76 study results through wk 76. Arthritis Rheum. 2010 ; 62 (Suppl 10). S606 - S606
49. Robb-Nicholson LC, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Br J Rheumatol. 1989 ; 28: 500-505 (Pubitemid 20004021)
50. Fergusson AG, Milne JA, Shand WN. Disseminated lupus erythematosus; notes on three fatal cases with a short review of the literature. Glasgow Med J. 1949 ; 30: 385-394
51. Decker JL, Steinberg AD, Reinertsen JL, Plotz PH, Balow JE, Klippel JH. NIH conference. Systemic lupus erythematosus: evolving concepts. Ann Intern Med. 1979 ; 91: 587-604 (Pubitemid 10230570)
52. Fries JF. Advances in management of rheumatic disease. 1965 to 1985. Arch Intern Med. 1989 ; 149: 1002-1011 (Pubitemid 19131821)
53. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2550-2557 (Pubitemid 44205016)
54. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009 ; 11: 229-229
55. Lau CS, Mak A. The socioeconomic burden of SLE. Nat Rev Rheumatol. 2009 ; 5: 400-404
56. Li T, Carls GS, Panopalis P, Wang S, Gibson TB, Goetzel RZ. Long-term medical costs and resource utilization in systemic lupus erythematosus and lupus nephritis: a five-year analysis of a large medicaid population. Arthritis Rheum. 2009 ; 61: 755-763
57. Wallace DJ. Improving the prognosis of SLE without prescribing lupus drugs and the primary care paradox. Lupus. 2008 ; 17: 91-92 (Pubitemid 351346441)
58. Mosca M, Tani C, Aringer M, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010 ; 69: 1269-1274
59. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009 ; 11: R109 - R109
60. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991 ; 34: 945-950
61. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 ; 135: 248-257 (Pubitemid 32799338)
62. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004 ; 350: 971-980 (Pubitemid 38269274)
63. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 ; 340: 741-745
64. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010 ; 69: 61-64
65. Grootscholten C, Ligtenberg G, Hagen EC, et al. Azathioprine/ methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int. 2006 ; 70: 732-742 (Pubitemid 44215349)
66. Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis. 2004 ; 43: 269-276 (Pubitemid 38146325)
67. Pepper R, Griffith M, Kirwan C, et al. Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 2009 ; 24: 3717-3723
68. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010 ; 62: 2458-2466
69. Bauerle M, Grunke M, Tony HP, et al. and GRAID investigators Safety and efficacy of rituximab in patients with systemic lupus erythematosus: the German registry of autoimmune diseases (GRAID). Ann Rheum Dis. 2010 ; 69 (Suppl 3). 685-685
70. Looney RJ. B cell-targeted therapies for systemic lupus erythematosus: an update on clinical trial data. Drugs. 2010 ; 70: 529-540
71. Favas C, Isenberg DA. B-cell-depletion therapy in SLE-what are the current prospects for its acceptance?. Nat Rev Rheumatol. 2009 ; 5: 711-716
72. Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 2009 ; 10: 816-824
73. Uppal S, Hayat S, Raghupathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus. 2009 ; 18: 690-697
74. Aringer M, Smolen JS. Therapeutic blockade of TNF in patients with SLE-Promising or crazy?. Autoimmun Rev. 2011 ;:
75. Lanata CM, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus. 2010 ; 19: 935-940
76. Stummvoll GH, Julius U, Derfler K, Aringer M. Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl. 2009 ; 10: 110-113
77. Papa ND, Raschi E, Moroni G, et al. Anti-endothelial cell IgG fractions from systemic lupus erythematosus patients bind to human endothelial cells and induce a pro-adhesive and a pro-inflammatory phenotype in vitro. Lupus. 1999 ; 8: 423-429 (Pubitemid 29423575)
78. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997 ; 314: 253-257 (Pubitemid 27047378)
79. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009 ; 68: 1428-1432
80. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ. 2010 ; 340: c2541 - c2541
81. Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005 ;: CD002859 - CD002859
82. Jung H, Bobba R, Su J, et al. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum. 2010 ; 62: 863-868
83. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010 ; 115: 2292-2299
84. Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the "CAPS Registry". J Autoimmun. 2009 ; 32: 240-245
85. Ioannou Y, Lambrianides A, Cambridge G, Leandro MJ, Edwards JC, Isenberg DA. B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres. Ann Rheum Dis. 2008 ; 67: 425-426 (Pubitemid 351281283)
86. Hauser AC, Hauser L, Pabinger-Fasching I, Quehenberger P, Derfler K, Horl WH. The course of anticardiolipin antibody levels under immunoadsorption therapy. Am J Kidney Dis. 2005 ; 46: 446-454 (Pubitemid 41208180)
87. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005 ; 64: 620-625 (Pubitemid 40469095)
88. Neuwelt CM, Young RG, McGhee RA, Freeman J. Role of rituximab in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus as monotherapy in combination therapy. Ann Rheum Dis. 2005 ; 64 (Suppl III). 57-57
89. Dorner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev. 2009 ; 9: 82-89
90. Vina ER, Fang AJ, Wallace DJ, Weisman MH. Chronic inflammatory demyelinating polyneuropathy in patients with systemic lupus erythematosus: prognosis and outcome. Semin Arthritis Rheum. 2005 ; 35: 175-184 (Pubitemid 41713957)
91. Levy Y, Uziel Y, Zandman G, et al. Response of vasculitic peripheral neuropathy to intravenous immunoglobulin. Ann N Y Acad Sci. 2005 ; 1051: 779-786 (Pubitemid 41362802)
92. Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003 ; 7: 173-182 (Pubitemid 36753913)
93. Harscher S, Rummler S, Oelzner P, et al. [Selective immunoadsorption in neurologic complications of systemic lupus erythematosus]. Nervenarzt. 2007 ; 78: 441-444 (Pubitemid 46599075)
94. Carneiro JR, Sato EI. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol. 1999 ; 26: 1275-1279 (Pubitemid 29268077)
95. Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008 ; 59: 1796-1804
96. Tam LS, Li EK, Wong CK, Lam CW, Szeto CC. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus. 2004 ; 13: 601-604 (Pubitemid 39145490)
97. Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006 ; 54: 2983-2988 (Pubitemid 44497779)
98. Abu-Shakra M, Shoenfeld Y. Azathioprine therapy for patients with systemic lupus erythematosus. Lupus. 2001 ; 10: 152-153 (Pubitemid 32410069)
99. Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus. 2005 ; 14: 856-858 (Pubitemid 41597624)
100. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus. 2003 ; 12: 633-635 (Pubitemid 37021801)
101. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus. 2003 ; 12: 630-632 (Pubitemid 37021800)
102. Griffiths B, Emery P. The treatment of lupus with cyclosporin A. Lupus. 2001 ; 10: 165-170 (Pubitemid 32410072)
103. Winkler A, Jackson RW, Kay DS, Mitchell E, Carmignani S, Sharp GC. High-dose intravenous cyclophosphamide treatment of systemic lupus erythematosus-associated aplastic anemia. Arthritis Rheum. 1988 ; 31: 693-694
104. Walport MJ, Hubbard WN, Hughes GR. Reversal of aplastic anaemia secondary to systemic lupus erythematosus by high-dose intravenous cyclophosphamide. Br Med J (Clin Res Ed). 1982 ; 285: 769-770 (Pubitemid 12058133)
105. Perrotta S, Locatelli F, La MA, Cennamo L, De SP, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol. 2002 ; 116: 465-467 (Pubitemid 34155523)
106. Lindholm C, Borjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 2008 ; 35: 826-833 (Pubitemid 351747123)
107. Maier WP, Gordon DS, Howard RF, et al. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Arthritis Rheum. 1990 ; 33: 1233-1239 (Pubitemid 20273312)
108. Lipnick RN, Tsokos GC, Bray GL, White PH. Autoimmune thrombocytopenia in pediatric systemic lupus erythematosus: alternative therapeutic modalities. Clin Exp Rheumatol. 1990 ; 8: 315-319 (Pubitemid 20239584)
109. Levy Y, Sherer Y, Ahmed A, et al. A study of 20 SLE patients with intravenous immunoglobulin-clinical and serologic response. Lupus. 1999 ; 8: 705-712
110. Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol. 2005 ; 29: 219-228 (Pubitemid 43041673)
111. Gomard-Mennesson E, Ruivard M, Koenig M, et al. Treatment of isolated severe immune hemolytic anaemia associated with systemic lupus erythematosus: 26 cases. Lupus. 2006 ; 15: 223-231
112. Hall S, McCormick JL, Greipp PR, Michet CJ, McKenna CH. Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus. Ann Intern Med. 1985 ; 102: 325-328
113. Alarcon-Segovia D. Splenectomy has a limited role in the management of lupus with thrombocytopenia. J Rheumatol. 2002 ; 29: 1-2 (Pubitemid 34041850)
114. Santilli D, Govoni M, Prandini N, Rizzo N, Trotta F. Autosplenectomy and antiphospholipid antibodies in systemic lupus erythematosus: A pathogenetic relationship?. Semin Arthritis Rheum. 2003 ; 33: 125-133 (Pubitemid 37386206)
115. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 ; 115: 168-186
116. Musio F, Bohen EM, Yuan CM, Welch PG. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus. Semin Arthritis Rheum. 1998 ; 28: 1-19 (Pubitemid 28378079)
117. Kwok SK, Ju JH, Cho CS, Kim HY, Park SH. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: a single centre study. Lupus. 2009 ; 18: 16-21
118. Niewold TB, Alpert D, Scanzello CR, Paget SA. Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease. J Rheumatol. 2006 ; 33: 1194-1196 (Pubitemid 43825477)
119. Hundae A, Peskoe S, Grimsley E, Patel S. Rituximab therapy for refractory thrombotic thrombocytopenic purpura and autoimmune-mediated thrombocytopenia in systemic lupus erythematosus. South Med J. 2008 ; 101: 943-944
120. Limal N, Cacoub P, Sene D, Guichard I, Piette JC. Rituximab for the treatment of thrombotic thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2008 ; 17: 69-71 (Pubitemid 351487024)
121. Letchumanan P, Ng HJ, Lee LH, Thumboo J. A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus. Rheumatology (Oxford). 2009 ; 48: 399-403
122. Kamiya K, Kurasawa K, Arai S, et al. Rituximab was effective on refractory thrombotic thrombocytopenic purpura but induced a flare of hemophagocytic syndrome in a patient with systemic lupus erythematosus. Mod Rheumatol. 2010 ; 20: 81-85
123. Brasington RD, Furst DE. Pulmonary disease in systemic lupus erythematosus. Clin Exp Rheumatol. 1985 ; 3: 269-276 (Pubitemid 15024965)
124. Erickson RW, Franklin WA, Emlen W. Treatment of hemorrhagic lupus pneumonitis with plasmapheresis. Semin Arthritis Rheum. 1994 ; 24: 114-123 (Pubitemid 24326549)
125. Santos-Ocampo AS, Mandell BF, Fessler BJ. Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. Chest. 2000 ; 118: 1083-1090
126. Chang MY, Fang JT, Chen YC, Huang CC. Diffuse alveolar hemorrhage in systemic lupus erythematosus: a single center retrospective study in Taiwan. Ren Fail. 2002 ; 24: 791-802
127. Nellessen CM, Poge U, Brensing KA, Sauerbruch T, Klehr HU, Rabe C. Diffuse alveolar haemorrhage in a systemic lupus erythematosus patient successfully treated with rituximab: a case report. Nephrol Dial Transplant. 2008 ; 23: 385-386 (Pubitemid 351767423)
128. Pinto LF, Candia L, Garcia P, et al. Effective treatment of refractory pulmonary hemorrhage with monoclonal anti-CD20 antibody (rituximab). Respiration. 2009 ; 78: 106-109
129. Eiser AR, Shanies HM. Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum. 1994 ; 37: 428-431 (Pubitemid 24093636)
130. Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. Arthritis Rheum. 1998 ; 41: 1215-1220 (Pubitemid 28313423)
131. Reynolds JA, Toescu V, Yee CS, Prabu A, Situnayake D, Gordon C. Effects of rituximab on resistant SLE disease including lung involvement. Lupus. 2009 ; 18: 67-73
132. Benham H, Garske L, Vecchio P, Eckert BW. Successful treatment of shrinking lung syndrome with rituximab in a patient with systemic lupus erythematosus. J Clin Rheumatol. 2010 ; 16: 68-70
133. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 ; 34: 1219-1263
134. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 ; 30: 2493-2537
135. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol. 2002 ; 29: 282-287 (Pubitemid 34118774)
136. Jais X, Launay D, Yaici A, et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008 ; 58: 521-531 (Pubitemid 351294886)
137. Rovensky J, Tuchynova A. Systemic lupus erythematosus in the elderly. Autoimmun Rev. 2008 ; 7: 235-239
138. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am. 1994 ; 20: 243-263 (Pubitemid 24066019)
139. Bitran J, McShane D, Ellman MH. Arthritis Rounds: Ascites as the major manifestation of systemic lupus erythematosus. Arthritis Rheum. 1976 ; 19: 782-785
140. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford). 2005 ; 44: 1542-1545 (Pubitemid 41742472)
141. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006 ; 65: 942-945
142. Hayat SJ, Uppal SS. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus. Mod Rheumatol. 2007 ; 17: 174-177 (Pubitemid 46614367)
143. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2009 ; 113: 214-223
144. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica. 2010 ; 95: 284-292
145. Wallace DJ. Apheresis for lupus erythematosus. Lupus. 1999 ; 8: 174-180 (Pubitemid 29186835)
146. McLeod BC. Introduction to the third special issue: clinical applications of therapeutic apheresis. J Clin Apher. 2000 ; 15: 1-5 (Pubitemid 30176810)
147. Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus. 2009 ; 18: 884-888
148. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous
149. van Vollenhoven RF, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis. 2010 ; 69 (Suppl 3). 74-74
150. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 ; 377: 721-731
151. Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009 ; 18: 547-555
152. Dall'Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 ; 56: 4142-4150 (Pubitemid 350262342)
153. Dorner T, Kaufmann J, Wegener WA, Teoh N, Goldenberg DM, Burmester GR. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006 ; 8: R74 - R74
154. Wallace DJ, Petri M, Olsen N, et al. MEDI-545, an anti-interferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007 ; 62 (Suppl 10). S526 - S527
155. Yao Y, Richman L, Higgs BW, et al. Neutralization of interferon-alpha/ beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009 ; 60: 1785-1796